INTRODUCTION
============

Septic shock remains an important cause of morbidity and mortality among critically ill patients; thus, the Surviving Sepsis Campaign guidelines have been going to consensus for septic shock management \[[@b1-acc-2018-00283]\]. The recent Surviving Sepsis Campaign guidelines recommend 1 hour of bundle therapy, which includes repeated lactate measurements when the initial lactate level is elevated \[[@b2-acc-2018-00283]\]. As an index for tissue hypoxia and accelerated aerobic metabolism, elevated serum lactate is associated with unfavorable outcomes among patients with severe illness \[[@b3-acc-2018-00283]\]. Although elevated serum lactate may not directly reflect tissue hypoxia, it is accompanied by a hypermetabolic state with enhanced glycolysis and hyperlactatemia in cases of severe illness, especially septic shock \[[@b3-acc-2018-00283]-[@b7-acc-2018-00283]\]. Serum lactate level is associated with mortality, and hospital mortality has been reported to increase linearly with increasing serum lactate level \[[@b8-acc-2018-00283]\]. Therefore, lactate-guided therapy with repeated measurements has also been recommended in the Surviving Sepsis Campaign \[[@b9-acc-2018-00283]\].

Lactate normalization is a proven prognosis marker among septic shock patients. Since Nguyen et al. \[[@b10-acc-2018-00283]\] reported that over 10% of lactate clearance reduced mortality by 11%, various studies have demonstrated the prognostic value of lactate clearance \[[@b5-acc-2018-00283],[@b11-acc-2018-00283]-[@b13-acc-2018-00283]\]. In the previous studies, not only lactate clearance but also repeated lactate measurements could predict mortality among septic shock patients \[[@b14-acc-2018-00283],[@b15-acc-2018-00283]\]. Moreover, other methods of using lactate levels to predict mortality have been investigated \[[@b16-acc-2018-00283]\].

In a recent study of pediatric septic shock patients, the lactate area score, defined as the sum of the area under the curve (AUC) of measured lactate levels, was an independent prognostic factor for mortality with an odds ratio (OR) of 1.143 and 95% confidence interval (CI) of 1.046--1.250 \[[@b17-acc-2018-00283]\]. However, there have not been enough studies of lactate area score in septic shock \[[@b13-acc-2018-00283],[@b17-acc-2018-00283]\]. In this study, we assessed the lactate area score to predict the 28-day mortality of adult septic shock patients. The objective of this study was to determine the prognostic value of the lactate area score of critically ill patients with septic shock.

MATERIALS AND METHODS
=====================

Setting and Study Population
----------------------------

This study was a retrospective analysis of a prospective data registry and was performed in the emergency department (ED) of Asan Medical Center with an annual census of more than 100,000 patients in the Republic of Korea. It was approved by the Research Ethics Committee of the Hospital (No. 2015-1253).

Between January 2010 and December 2017, all adult patients with septic shock who were diagnosed in the ED and treated with protocol-driven resuscitation bundle therapy were enrolled with their data prospectively collected in our institution's Septic Shock Registry. Septic shock was defined as refractory hypotension with a systolic blood pressure of \<90 mmHg or a mean arterial pressure of \<70 mmHg requiring vasopressors despite adequate fluid resuscitation or a blood lactate concentration of at least 4 mmol/L \[[@b9-acc-2018-00283]\].

Exclusion criteria were as follows: patients with a "do not attempt resuscitation" status, patients who were transferred to another hospital during initial resuscitation, and patients who lacked data for repeated lactate measurements. In addition, we excluded patients with missing data of five times on repeated lactate levels.

Data Collection
---------------

Patient demographics and clinical data, including age, sex, past medical history, initial vital signs, laboratory results (such as white blood cell count, prothrombin time, and the levels of hemoglobin, platelet, aspartate transaminase, alanine transaminase, total bilirubin, blood urea nitrogen, creatinine, albumin, and lactate), and disease severity determined by the Sequential Organ Failure Assessment (SOFA) score, were retrieved from the Septic Shock Registry ([Table 1](#t1-acc-2018-00283){ref-type="table"}).

Lactate levels in arterial blood were measured using a blood gas analyzer (GEM Premier 3,000, display range, 0.3 to 15.0 mmol/L; Instrumentation Laboratory, Bedford, MA, USA). We measured the lactate level at the time of shock recognition (T~1~), which was repeated at 2, 4, 6, and 12 hours following the initial measurement (T~2~, T~3~, T~4~, T~5,~). The lactate area score was defined as the sum of the AUC of serial lactate levels (L~1~, L~2~, L~3~, L~4~, L~5~) measured for 12 hours using the trapezoidal rule, divided by the time interval \[[@b17-acc-2018-00283]\].
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The maximum lactate level was the highest level of lactate obtained from serial lactate measurements (five times). The primary clinical outcome of this study was the 28-day mortality rate. We evaluated the predictive ability of each lactate level (L~1~, L~2~, L~3~, L~4~, L~5~), the maximum lactate level, and the lactate area score.

Statistical Aanalysis
---------------------

Continuous variables are presented as the means with differences or medians with interquartile ranges, which were compared between patients by independent t-test and Mann-Whitney test. Categorical variables are summarized as frequencies and percentages, and differences between two groups were analyzed by Fisher's exact test.

To evaluate the relationship between mortality and lactate variables, univariate and multivariate logistic regression analyses with backward elimination were performed. We presented the OR with 95% CI for each model. The factors associated with mortality such as past history of stroke, infection site of urinary tract, laboratory tests of platelet, prothrombin time, albumin, blood urea nitrogen, creatinine, C-reactive protein, initial lactate, maximum lactate, severity factors of lactate and lactate area score were included in a multivariate logistic regression model. The model performance was evaluated using the receiver operating characteristic (ROC) curve with the AUC of each ROC curve. We considered P\<0.05 as statistically significant for all of the analyses.

RESULTS
=======

Baseline Characteristics of the Study Population
------------------------------------------------

A total of 362 adult patients were enrolled in this study, and their 28-day mortality was 31.8% ([Figure 1](#f1-acc-2018-00283){ref-type="fig"}). When we divided patients into the survivor and non-survivor group, age, sex, initial vital signs, and past medical history were not significantly different except for stroke, which was more frequent in the survivor group (88.0% vs. 12.0%, P=0.027). However, the SOFA score (median \[interquartile range\], 10.0 \[8.0 to 13.0\] vs. 13.0 \[11.0 to 16.0\]; P\<0.001) and lactate area score (38.8 \[22.7 to 58.0\] vs. 57.0 \[33.9 to 98.0\]; P\<0.001) were significantly higher in the non-survivor group, whereas urinary tract infection was significantly frequent in survivor group (8.1% vs. 1.7%, P=0.018) ([Table 1](#t1-acc-2018-00283){ref-type="table"}).

Laboratory Findings of Survivors and Non-survivors
--------------------------------------------------

In the non-survivor group, the platelet count was lower (183.5 vs. 140.5×10^3^/μl, P=0.049), prothrombin time was longer (1.3 vs. 1.4, P=0.001), and albumin level was lower (2.8 vs. 2.5 mg/ dl, P\<0.001); however, the levels of blood urea nitrogen (27.5 vs. 30.5 mg/dl, P=0.042), creatinine (1.4 vs. 1.6 mg/dl, P=0.004), and C-reactive protein (8.1 vs. 15.8 mg/dl, P=0.009) were higher. All serial lactate levels and the maximum lactate level were significantly higher in the non-survivor group (4.2 vs. 4.9, 3.3 vs. 4.7, 2.8 vs. 4.2, 2.7 vs. 4.5, 2.6 vs. 4.6, and 5.4 vs. 7.3 mmol/L with P=0.003, P=0.001, P\<0.001, P\<0.001, P\<0.001, and P\<0.001, respectively) ([Table 2](#t2-acc-2018-00283){ref-type="table"}).

Predicting 28-Day Mortality
---------------------------

We analyzed disease severity using a logistic regression model, which revealed that the SOFA score and lactate area score were highly associated with 28-day mortality (OR, 1.126; 95% CI, 1.060 to 1.197 and OR, 1.016; 95% CI, 1.010 to 1.022, respectively). In multivariate analysis, the lactate area score (OR, 1.013; 95% CI, 1.007 to 1.019), serum albumin (OR, 0.586; 95% CI, 0.407 to 0.843), and SOFA score (OR, 1.082; 95% CI, 1.014 to 1.153) were significantly associated with mortality ([Table 3](#t3-acc-2018-00283){ref-type="table"}).

A comparison of the AUC of the ROC curve between the initial lactate, maximum lactate, and lactate area score revealed that the lactate area score was higher (AUC \[95% CI\]: 0.596 \[0.532 to 0.659\], 0.635 \[0.572 to 0.698\], and 0.659 \[0.597 to 0.720\], respectively) ([Table 4](#t4-acc-2018-00283){ref-type="table"}, [Figure 2](#f2-acc-2018-00283){ref-type="fig"}). However, the difference between the maximum lactate and lactate area score was not statistically significant (P=0.071).

DISCUSSION
==========

In this study, we found that the lactate area score obtained from serial lactate measurements was independently associated with 28-day mortality among septic shock patients in the ED. However, the OR of the lactate area score for predicting mortality was not only lower than that in previous studies, which involved pediatric septic shock patients, but also lower than the SOFA score.

Although the initial lactate level is a biomarker that can be used to determine the prognosis and severity of septic shock \[[@b18-acc-2018-00283]\], it represents only the initial status and cannot reflect the effect of initial resuscitation. As serial lactate measurements reflect the response to the initial management, they may be a suitable predictor. In this study, the initial lactate level as well as L~2~, L~3~, L~4~, and L~5~ were associated with mortality ([Table 2](#t2-acc-2018-00283){ref-type="table"}). However, the discrepancy in the median values between survivors and non-survivors was increased with time (T~1~, 0.7 mmol/L; T~2~, 1.4 mmol/L; T~3~, 1.4 mmol/L; T~4~, 1.8 mmol/L; and T~5~, 2.0 mmol/L). This result indicated that the prognostic value of lactate levels may increase with time. Our previous study showed that the optimal timing of lactate remeasurements for predicting mortality was 6 hours from shock development \[[@b15-acc-2018-00283]\].

In studies by Kim et al. \[[@b17-acc-2018-00283]\] and Wang et al. \[[@b13-acc-2018-00283]\], the use of the lactate area score as a predictor of mortality has been proposed. In contrast to the initial lactate level, the exposure time to ischemia was considered by quantifying the accumulations of lactate at each time. In both studies, serial lactate measurements were performed in the early phase of septic shock for 24 hours every 6 hours from ICU admission, and the lactate area score was calculated using the trapezoidal rule. They demonstrated that the score was significantly associated with mortality. However, considering lactate kinetics, repeated lactate measurements for 24 hours might be too long to accurately reflect early mortality among septic shock patients \[[@b12-acc-2018-00283],[@b19-acc-2018-00283]-[@b21-acc-2018-00283]\]. In this study, we measured lactate levels for 12 hours (every 2 hours in the initial 6 hours) to give a more precise prognosis. The lactate area score was an independent predictor of mortality among adult septic shock patients (OR, 1.013; 95% CI, 1.007 to 1.019\] in multivariate analysis. In the AUC of the ROC curve, the lactate area score was higher than the initial and maximum lactate levels. Although this result was similar to that of previous studies, the AUC value was lower, and the difference from the maximum lactate level was not statistically significant \[[@b13-acc-2018-00283],[@b17-acc-2018-00283]\]. Unlike previous studies, our study was conducted in the very early phase of septic shock in the ED and not the ICU. In addition, we measured lactate levels more frequently (five times) within 12 hours. The association might be decreased because initial resuscitation includes hemodynamic stabilization, and early antibiotic administration is crucial for reducing mortality \[[@b2-acc-2018-00283],[@b22-acc-2018-00283]\]. Although the lactate area score may be an independent predictor, its statistical relevance is limited.

There are several limitations in our study. First, it was a retrospective observational study in a single medical center. Although a large number of patients were included, many patients with missing data on serial lactate levels were excluded. Multiple measurements of lactate levels might include patients with more severe illness, and it can dilute the results of lactate area score assessment due to severe illness in the comparisons. Since the same reason, AUC of lactate area score might lower than other studies. The overall 28-day mortality was higher than that of other similarly designed studies involving patients with septic shock (26.2%--36%) \[[@b17-acc-2018-00283],[@b23-acc-2018-00283],[@b24-acc-2018-00283]\]. One more important limitation was that the calculation method is not easy.

Despite these limitations, the early lactate area score may be an possible prognostic marker for predicting the 28-day mortality of adult septic shock patients. To generalize our results, further prospective multicenter interventional studies should be conducted to validate our results.

KEY MESSAGES
============

▪ The lactate area score is the sum of the area under the curve of serial lactate levels from repeated measurements using the trapezoidal rule, divided by the time interval.

▪ The study involved adult septic shock patients in the emergency department, and measurements were performed within 12 hours from shock recognition.

▪ The lactate area score may be an early prognostic marker of 28-day mortality.

**CONFLICT OF INTEREST** No potential conflict of interest relevant to this article was reported.

**AUTHOR CONTRIBUTIONS**

Conceptualization: SMR. Data curation: SJ. Formal analysis: GY, YJK. Funding acquisition: SMR. Methodology: SJY. Project administration: SHL. Visualization: JSK. Writing -- original draft: GY. Writing -- review & editing: SMR, WYK.

We thank Min-Ju Kim (Department of Medical Statistics, Asan Medical Center, Seoul, Korea) for help with statistical analysis.

![Flowchart of the selection and classification of patients.](acc-2018-00283f1){#f1-acc-2018-00283}

![Receiver operating characteristic and area under the curve (AUC) in lactate area score, maximum lactate, and initial lactate.](acc-2018-00283f2){#f2-acc-2018-00283}

###### 

Baseline characteristics of the study population

  Characteristics                    All patients (n=362)   Survivor (n=247)    Non-survivor (n=115)   P-value
  ---------------------------------- ---------------------- ------------------- ---------------------- ---------
  Age (yr)                           64.3±12.5              64.1±12.4           64.7±12.9              0.669
  Male sex                           242 (66.9)             164 (66.4)          78 (67.8)              0.812
  Past medical history                                                                                 
   Hypertension                      108 (29.8)             77 (31.2)           31 (27.0)              0.460
   Diabetes                          74 (20.4)              48 (19.4)           26 (22.6)              0.485
   Stroke                            25 (6.9)               22 (8.9)            3 (2.6)                0.027
   Coronary artery disease           40 (11.0)              27 (10.9)           13 (11.3)              1.000
   Chronic lung disease              56 (15.5)              37 (15.0)           19 (16.5)              0.755
   Liver cirrhosis                   52 (14.4)              34 (13.8)           18 (15.7)              0.371
  Vital sign                                                                                           
   Systolic blood pressure (mmHg)    106.5±31.6             106.1±30.8          107.4±33.4             0.705
   Diastolic blood pressure (mmHg)   65.7±22.0              65.6±51.6           65.9±23.2              0.931
   Respiratory rate (rates/min)      22.0 (20.0--30.6)      21.0 (20.0--28.0)   22.0 (20.0--26.0)      0.195
   Pulse rate (beats/min)            105.1±31.6             103.8±30.3          108.0±34.2             0.101
   Body temperature (°C)             37.5±1.4               37.5±1.4            37.5±1.3               0.125
  Severity                                                                                             
   SOFA score                        11.0 (8.0--14.8)       10.0 (8.0--13.0)    13.0 (11.0--16.0)      \<0.001
   Lactate area score                43.7 (26.4--71.4)      38.8 (22.7--58.0)   57.0 (33.9--98.0)      \<0.001
  Presumed site of infection                                                                           
   Respiratory tract                 155 (42.8)             98 (39.7)           57 (49.6)              0.077
   Urinary tract                     22 (6.1)               20 (8.1)            2 (1.7)                0.018
   Gastrointestinal tract            40 (11.0)              27 (10.9)           13 (11.3)              0.916
   Hepato-biliary tract              82 (22.7)              63 (25.5)           19 (16.5)              0.057
   Bone or soft tissue               16 (4.4)               9 (3.6)             7 (6.1)                0.292
   Other                             44 (12.2)              28 (11.3)           16 (13.9)              0.485

Values are presented as mean±standard deviation, number (%), or median (interquartile range).

SOFA: Sequential Organ Failure Assessment.

###### 

Laboratory findings of survivors and non-survivors

  Characteristics                 Survivor (n=247)      Non-survivor (n=115)   P-value
  ------------------------------- --------------------- ---------------------- ---------
  White blood cell (×10³/μl)      11.6 (4.9--19.1)      9.9 (4.6--18.0)        0.688
  Hemoglobin (g/dl)               11.6±2.8              11.3±2.7               0.393
  Platelet (×10³/μl)              183.5 (94.0--268.3)   140.5 (49.0--186.3)    0.049
  Aspartate transaminase (IU/L)   44.0 (28.0--74.3)     46.0 (27.0--197.5)     0.664
  Alanine transaminase (IU/L)     25.0 (14.8--46.3)     33.5 (14.0--69.3)      0.842
  Total bilirubin (mg/dl)         1.0 (0.6--2.3)        1.3 (0.7--3.2)         0.435
  Prothrombin time (INR)          1.3 (1.1--1.6)        1.4 (1.2--2.0)         0.001
  Albumin (mg/dl)                 2.8±0.7               2.5±0.6                \<0.001
  Blood urea nitrogen (mg/dl)     27.5 (17.0--41.3)     30.5 (18.8--47.0)      0.042
  Creatinine (mg/dl)              1.4 (1.0--2.6)        1.6 (1.1--2.3)         0.004
  C-reactive protein (mg/dl)      8.1 (3.0--20.5)       15.8 (7.4--24.0)       0.009
  Initial lactate (mmol/L)        4.2 (2.4--6.6)        4.9 (3.4--10.5)        0.003
  2-Hour lactate (mmol/L)         3.3 (1.9--5.4)        4.7 (2.3--7.5)         0.001
  4-Hour lactate (mmol/L)         2.8 (1.7--4.7)        4.2 (2.2--8.2)         \<0.001
  6-Hour lactate (mmol/L)         2.7 (1.6--4.5)        4.5 (2.3--8.1)         \<0.001
  12-Hour lactate (mmol/L)        2.6 (1.6--4.8)        4.6 (2.6--9.9)         \<0.001
  Maximum lactate (mmol/L)        5.4 (3.2--8.1)        7.3 (4.2--13.2)        \<0.001

Values are presented as median (interquartile range) or mean±standard deviation.

INR: international normalized ratio.

###### 

Multivariate analysis for predicting 28-day mortality

  Characteristics                  Univariate OR (95% CI)   Multivariate OR (95% CI)   P-value
  -------------------------------- ------------------------ -------------------------- ---------
  Stroke                           0.274 (0.080--0.935)                                
  Urinary tract infection          0.201 (0.046--0.875)                                
  Platelet (×10³/μl)               0.999 (0.997--1.001)                                
  Prothrombin time (INR)           1.141 (0.979--1.330)                                
  Albumin (mg/dl)                  0.489 (0.347--0.690)     0.586 (0.407--0.843)       0.004
  Blood urea nitrogen (mg/dl)      1.007 (0.998--1.016)                                
  Creatinine (mg/dl)               1.136 (1.001--1.289)                                
  C-reactive protein (mg/dl)       1.023 (1.003--1.042)                                
  Initial lactate (mmol/L)         1.100 (1.038--1.165)                                
  Maximum lactate (mmol/L)         1.143 (1.081--1.209)                                
  SOFA score                       1.126 (1.060--1.197)     1.082 (1.014--1.153)       0.017
  Lactate area score (mmol/L×hr)   1.016 (1.010--1.022)     1.013 (1.007--1.019)       \<0.001

Multivariate analysis included logistic regression analysis and backward elimination.

OR: odds ratio; CI: confidence interval; INR: international normalized ratio; SOFA: Sequential Organ Failure Assessment.

###### 

Comparison of the AUC between the initial lactate, maximum lactate, and lactate area score

  Variable                         AUC     95% CI         P-value
  -------------------------------- ------- -------------- ---------
  Initial lactate (mmol/L)         0.596   0.532--0.659   0.003
  Maximum lactate (mmol/L)         0.635   0.572--0.698   \<0.001
  Lactate area score (mmol/L×hr)   0.659   0.597--0.720   \<0.001

AUC: area under the curve; CI: confidence interval.

[^1]: These authors contributed equally to this article.
